TY - JOUR
T1 - d-Cycloserine-Augmented Behavior Therapy for Body Dysmorphic Disorder
T2 - A Preliminary Efficacy Trial
AU - Weingarden, Hilary
AU - Mothi, Suraj S.
AU - Ladis, Ilana
AU - Hoeppner, Susanne
AU - Reese, Hannah E.
AU - Timpano, Kiara
AU - Siev, Jedidiah
AU - Rasmussen, Jessica
AU - Ragan, Jennifer
AU - Dougherty, Darin D.
AU - Wilhelm, Sabine
N1 - Funding Information:
placebo from Forest Laboratories for clinical trials funded by the NIH. Dr. Wilhelm is a presenter for the Massachusetts General Hospital Psychiatry Academy in educational programs supported through independent medical education grants from pharmaceutical companies; she has received royalties from Elsevier Publications, Guilford Publications, New Harbinger Publications, and Oxford University Press. Dr. Wilhelm has also received speaking honorarium from various academic institutions and foundations, including the International Obsessive Compulsive Disorder Foundation and the Tourette Association of America. In addition, she received payment from the Association for Behavioral and Cognitive Therapies for her role as Associate Editor for the Behavior Therapy journal, as well as from John Wiley & Sons, Inc. for her role as Associate Editor on the journal Depression & Anxiety. Dr. Wilhelm has also received salary support from Novartis. Dr. Dougherty has received research support from Medtronic and Li-vaNova. Suraj S. Mothi, Susanne Hoeppner, Hannah E. Reese, Kiara Timpano, Jedidiah Siev, Jessica Rasmussen and Jennifer Ragan declare that they have no conflict of interest.
Funding Information:
Funding This work was supported by the Neil and Anna Rasmussen Foundation and the David Judah Fund. The funding sources played no role in design of this study; the collection, analysis, and interpretation of data; the writing of this report; or the decision to submit this article for publication.
Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/10/15
Y1 - 2019/10/15
N2 - Cognitive behavioral therapy (CBT) is the leading psychotherapeutic treatment for body dysmorphic disorder (BDD), yet not all patients improve. To address the treatment response gap, CBT may be augmented with cognitive enhancers such as d-cycloserine (DCS). DCS-augmented behavior therapy has been tested with mixed results in related disorders. To initially test whether DCS may augment CBT for BDD, we conducted the first preliminary efficacy trial of DCS versus placebo-augmented CBT for BDD, via a randomized, double-blind study. We analyzed data using mixed-effects models in a modified intent-to-treat sample (N = 26). Over 10 weeks of treatment, primary (BDD severity) and secondary (insight, depression) outcomes improved significantly across both conditions, but there were no significant group differences in response. Exploratory analysis revealed that BDD-related distress, specifically, reduced significantly more in the DCS condition compared to placebo. This is the first study testing DCS-augmented CBT for BDD. Implications, limitations, and future directions are discussed. Trial registry: ClinicalTrials.gov Identifier NCT00842309.
AB - Cognitive behavioral therapy (CBT) is the leading psychotherapeutic treatment for body dysmorphic disorder (BDD), yet not all patients improve. To address the treatment response gap, CBT may be augmented with cognitive enhancers such as d-cycloserine (DCS). DCS-augmented behavior therapy has been tested with mixed results in related disorders. To initially test whether DCS may augment CBT for BDD, we conducted the first preliminary efficacy trial of DCS versus placebo-augmented CBT for BDD, via a randomized, double-blind study. We analyzed data using mixed-effects models in a modified intent-to-treat sample (N = 26). Over 10 weeks of treatment, primary (BDD severity) and secondary (insight, depression) outcomes improved significantly across both conditions, but there were no significant group differences in response. Exploratory analysis revealed that BDD-related distress, specifically, reduced significantly more in the DCS condition compared to placebo. This is the first study testing DCS-augmented CBT for BDD. Implications, limitations, and future directions are discussed. Trial registry: ClinicalTrials.gov Identifier NCT00842309.
KW - Behavior therapy
KW - Body dysmorphic disorder
KW - Cognitive enhancers
KW - d-Cycloserine
UR - http://www.scopus.com/inward/record.url?scp=85062637999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062637999&partnerID=8YFLogxK
U2 - 10.1007/s10608-019-10015-0
DO - 10.1007/s10608-019-10015-0
M3 - Article
AN - SCOPUS:85062637999
VL - 43
SP - 937
EP - 947
JO - Cognitive Therapy and Research
JF - Cognitive Therapy and Research
SN - 0147-5916
IS - 5
ER -